Funder: Pfizer Inc.

Due Dates: May 18, 2026 (Submission Deadline, full application due by 23:59 EST)

Funding Amounts: Up to $125,000 per project; 2–3 awards expected; overhead capped at 28%.

Summary: Supports educational initiatives to improve healthcare professional competency in BCMA Bi-Specific Antibody therapy management for relapsed/refractory multiple myeloma.